Natalia Buza, MD
DownloadHi-Res Photo
Cards
Appointments
Pathology
Primary
Titles
Director, Pathology Center of Excellence for Women’s Health, Anatomic Pathology; Director, Gynecologic Pathology Fellowship Program, Anatomic Pathology
Contact Info
Appointments
Pathology
Primary
Titles
Director, Pathology Center of Excellence for Women’s Health, Anatomic Pathology; Director, Gynecologic Pathology Fellowship Program, Anatomic Pathology
Contact Info
Appointments
Pathology
Primary
Titles
Director, Pathology Center of Excellence for Women’s Health, Anatomic Pathology; Director, Gynecologic Pathology Fellowship Program, Anatomic Pathology
Contact Info
About
Titles
Professor of Pathology
Director, Pathology Center of Excellence for Women’s Health, Anatomic Pathology; Director, Gynecologic Pathology Fellowship Program, Anatomic PathologyBiography
Dr. Buza completed her residency training in Anatomic Pathology, followed by a Fellowship in Gynecologic and Breast pathology at Yale University. She joined the faculty at Yale in 2010 where she is currently Professor of Pathology, Director of Pathology Center of Excellence for Women’s Health, and Director of the Gynecologic Pathology Fellowship Program. Dr. Buza authored/co-authored over 140 publications in the field of gynecologic pathology, including several review articles, book chapters, and a textbook dedicated to Intraoperative Frozen Section in Gynecologic Pathology. Most recently she contributed to multiple sections of the 5th edition of WHO Classification of Female Genital Tumours.
Dr. Buza has been course faculty at the American Society for Clinical Pathology (ASCP) and United States and Canadian Academy of Pathology (USCAP) annual meetings, and at the USCAP Interactive Microscopy Center. Dr. Buza also served on the Abstract Review Board of USCAP, and she is an editorial board member of Modern Pathology, International Journal of Gynecological Pathology, and Human Pathology. Her main areas of academic interest include diagnostic, prognostic, and predictive markers of endometrial carcinoma, ovarian sex cord – stromal tumors, and gestational trophoblastic disease.
Appointments
Pathology
ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellowship
- Yale School of Medicine (2010)
- Residency
- Yale University School of Medicine (2009)
- MD
- University of Pecs Med and Health Science Center (1999)
Research
Overview
Medical Subject Headings (MeSH)
Gestational Trophoblastic Disease; Morphological and Microscopic Findings; Ovarian Neoplasms; Pathological Conditions, Anatomical; Uterine Cervical Neoplasms; Uterine Neoplasms; Vulvar Neoplasms
ORCID
0000-0002-0008-334X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Natalia Buza's published research.
Publications Timeline
A big-picture view of Natalia Buza's research output by year.
Research Interests
Research topics Natalia Buza is interested in exploring.
Pei Hui, PhD, MD
Alessandro Santin, MD
Gloria Huang, MD, FACOG
Stefania Bellone, PhD
Peter Schwartz, MD
Mitchell Clark, MD, MPH
88Publications
1,350Citations
Uterine Neoplasms
Ovarian Neoplasms
Uterine Cervical Neoplasms
Gestational Trophoblastic Disease
Publications
2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 1-11. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerClear cell carcinomaHER2-targeting antibody-drug conjugateAntibody-drug conjugatesT-DXdReceptor over-expressionTrastuzumab deruxtecanXenograft modelCell linesOvarian clear cell carcinomaOvarian cancer cell linesTumors overexpressing HER2Biologically aggressive tumorsFluorescence in situ hybridization assaySerous ovarian cancerEffective antibody-drug conjugatesIn vivo antitumor activityMouse xenograft modelMetastatic cell linesDS-8201aCancer cell linesAggressive tumorsHER2 expressionCell carcinomaOvarian cancerDiandric triploid partial mole versus digynic nonmolar triploidy: is morphological assessment sufficient for the diagnostic distinction?
Nagy A, Niu N, Sun T, Buza N, Hui P. Diandric triploid partial mole versus digynic nonmolar triploidy: is morphological assessment sufficient for the diagnostic distinction? Histopathology 2024 DOI: 10.1111/his.15247.Peer-Reviewed Original ResearchConceptsPositive predictive valueTriploid gestationsPartial moleTrophoblastic hyperplasiaVillous sizeCistern formationHistological parametersPostmolar gestational trophoblastic neoplasiaTriploid partial molesGenotype-phenotype correlation studiesGestational trophoblastic neoplasiaPartial hydatidiform moleModerate interobserver agreementVillous populationsTrophoblastic neoplasiaGestational weeksHydatidiform moleClinical presentationPatient ageDigynic triploidyAbnormal histologyInterobserver agreementGestationSyncytiotrophoblastHistological assessmentRandomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchConceptsPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-freePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatientsTargetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations.
Manrai P, McHenry A, Sun T, Santin A, Ratner E, Lin D, Elvin J, Hui P, Buza N. Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations. International Journal Of Gynecological Pathology 2024 PMID: 38914011, DOI: 10.1097/pgp.0000000000001050.Peer-Reviewed Original ResearchConceptsEndometrial carcinomaGynecologic malignanciesTyrosine kinase domainHER2-mutated non-small cell lung cancerTargeted anti-HER2 therapyNon-small cell lung cancerHigh-grade endometrioid adenocarcinomasFam-trastuzumab deruxtecanOvarian mucinous adenocarcinomaAnti-HER2 therapyAnti-HER2 drugsHER2 3+US Food and Drug AdministrationCell lung cancerEndometrial serous carcinomaSolid tumor typesStandard treatment recommendationsFood and Drug AdministrationFluorescence in situ hybridizationGynecological cancer typesEndometrial primaryMullerian originSerous carcinomaHER2 IHCEndometrioid adenocarcinomaRandomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimodCorrection: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.Peer-Reviewed Original ResearchAltmetricNovel FOXL2 Mutation in an Ovarian Adult Granulosa Cell Tumor: Report of a Case With Diagnostic and Clinicopathologic Implications.
Nagy A, Niu N, Ratner E, Hui P, Buza N. Novel FOXL2 Mutation in an Ovarian Adult Granulosa Cell Tumor: Report of a Case With Diagnostic and Clinicopathologic Implications. International Journal Of Gynecological Pathology 2024 PMID: 38426544, DOI: 10.1097/pgp.0000000000001024.Peer-Reviewed Original ResearchCitationsConceptsAdult granulosa cell tumorGranulosa cell tumorsOvarian sex cord-stromal tumorsSex cord-stromal tumorsCord-stromal tumorsCell tumorsFOXL2 mutationMutation c.Fibromatous stromaMalignant ovarian sex cord-stromal tumorAdjuvant vaginal cuff brachytherapyOvarian adult granulosa cell tumorsBilateral salpingo-oophorectomyRight ovarian massVaginal cuff brachytherapyAtypical endometrial hyperplasiaSuperficial myometrial invasionRoutine molecular testingUniform tumor cellsEndometrioid endometrial adenocarcinomaNested growth patternPoint mutation c.Months follow-upSalpingo-oophorectomyTotal hysterectomy
2023
Ovarian Leydig Cell Tumor Associated with Recurrent Torsion and Virilization in an Adolescent Patient
Roth L, Smith A, Buza N, Coons B, Stitelman D, Vash-Margita A. Ovarian Leydig Cell Tumor Associated with Recurrent Torsion and Virilization in an Adolescent Patient. Journal Of Pediatric And Adolescent Gynecology 2023, 37: 217-219. PMID: 38110028, DOI: 10.1016/j.jpag.2023.11.014.Peer-Reviewed Original ResearchCitationsConceptsPolycystic ovarian syndromeOvarian tumorsCell tumorsRecurrent ovarian torsionAbnormal uterine bleedingPost-menopausal womenLeydig cell tumorUterine bleedingOvarian syndromeOvarian torsionYounger patientsOvarian functionOvarian hilumAdolescent patientsNodular proliferationSecrete androgensTumor AssociatedRecurrent torsionPrimary amenorrheaCurrent recommendationsReinke crystalsTumorsLeydig cellsIncidence increasesVirilizationExtrauterine epithelioid trophoblastic tumour and its somatic carcinoma mimics: short tandem repeat genotyping meets the diagnostic challenges
Niu N, Ordulu Z, Burak Z, Buza N, Hui P. Extrauterine epithelioid trophoblastic tumour and its somatic carcinoma mimics: short tandem repeat genotyping meets the diagnostic challenges. Histopathology 2023, 84: 325-335. PMID: 37743102, DOI: 10.1111/his.15054.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsEpithelioid trophoblastic tumorGestational trophoblastic tumorsTrophoblastic tumorExtrauterine sitesSomatic carcinomasDifferential diagnosisDiagnosis of ETTExtrauterine epithelioid trophoblastic tumorsTriple-negative breast carcinomaTrophoblastic differentiationMetastatic triple-negative breast carcinomaPrimary lung carcinomaMain differential diagnosisMajor differential diagnosisEctopic gestationImmunohistochemical featuresDiagnostic challengeMetastatic tumorsLung carcinomaBreast carcinomaPatient managementEpithelioid malignanciesImmunohistochemical levelCarcinomaTumor tissueIn Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsUterine serous carcinomaAntibody-dependent cellular cytotoxicityT-DXdUSC patientsUSC cell linesTrastuzumab deruxtecanSerous carcinomaHER2 expressionClinical trialsRecurrent uterine serous carcinomaTopoisomerase I inhibitor payloadSignificant antibody-dependent cellular cytotoxicityCell linesMultiple tumor indicationsPrimary USC cell linesLow HER2 expressionFuture clinical trialsHigh recurrence ratePeripheral blood lymphocytesERBB2 gene amplificationGrowth suppressionHER2-overexpressing cell linesTumor growth suppressionOverall survivalStandard chemotherapy
Clinical Trials
Current Trials
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer
HIC ID2000023639RoleSub InvestigatorPrimary Completion Date06/01/2026Recruiting ParticipantsA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
HIC ID2000026850RoleSub InvestigatorPrimary Completion Date12/31/2024Recruiting Participants
Academic Achievements and Community Involvement
activity Editor
Journal ServiceInternational Journal of Gynecological PathologyDetails2016 - PresentDescriptionEditorial Board Memberactivity Editor
Journal ServiceHuman PathologyDetails2018 - PresentDescriptionEditorial Board Memberactivity Editor
Journal ServiceModern PathologyDetails2021 - PresentDescriptionEditorial Board Memberhonor The Averill A. Liebow Award for Excellence in the Teaching of Pathology Residents
Yale School of Medicine AwardDetails06/30/2016United States
Clinical Care
Overview
As a pathologist specializing in gynecologic and breast cancers and diseases, Natalia Buza, MD, rarely sees the patients she spends many hours thinking about; her work is done not in an exam room, but behind a high-powered microscope. This doesn’t make her patients any less real, however. Dr. Buza explains that she became a pathologist because “it’s an exciting discipline and so important for patient care.”
Working closely with gynecologic cancer doctors, Dr. Buza examines samples of patients’ tissue taken for a biopsy to look for signs of endometrial, ovarian and cervical cancers. Once a cancer has been identified, she continues her examination of the cells, specifying the tumor subtype and looking for specific markers at the protein and genetic level that could help the patient’s physician create a personalized cancer treatment plan. Also, she notes, “I do a lot of collaborative research and studies.” For example, she and other colleagues recently investigated the possibility of using targeted anti-HER2 therapy in certain endometrial cancers.
Dr. Buza is an associate professor of pathology and associate director of gynecologic pathology at Yale School of Medicine.
Clinical Specialties
Pathology; Anatomic Pathology; Gynecological Pathology
Board Certifications
Anatomic Pathology
- Certification Organization
- AB of Pathology
- Latest Certification Date
- 2020
- Original Certification Date
- 2009
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
- April 09, 2024
Topical Shows Promise in Treating Precancerous Cervical Condition
- November 07, 2023
Yale Diagnostic Pathology Annual CME Review held in NYC
- July 07, 2023Source: Medicine
Bibliometric and Visualized Analysis of Highly Cited Articles on Immunotherapy for Endometrial Cancer
Get In Touch
Contacts
Appointment Number
Clinical Inquiry Number
Clinic Fax Number
Locations
Department of Pathology
Academic Office
Brady Memorial Laboratory
310 Cedar Street, Wing Lauder Hall, Fl 2nd, Ste LH 219B
New Haven, CT 06510
Fax
203.737.1064Clinical Inquiry
203.737.5292Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.